BMO Capital Markets Has Lowered Expectations for Vertex …

BMO Capital Markets Has Lowered Expectations For Vertex …

1 week from now

Dec 20, 2024  · BMO Capital Markets lowered their target price on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an "outperform" rating on the stock in a …

marketbeat.com

Vertex Pharmaceuticals Price Target Lowered To $520 From $566 At …

1 week from now

Dec 20, 2024  · BMO Capital lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $566 but keeps an Outperform rating on the shares. The company’s Suzetrigine …

nasdaq.com

BMO Cuts Vertex Target To $520, Stays Positive On Drug Outlook

1 week from now

Dec 20, 2024  · BMO Capital Markets anticipates that the approval and subsequent launch of suzetrigine for acute pain, expected in January 2025, will surpass current market expectations.

investing.com

BMO Cuts Vertex Target To $520, Stays Positive On Drug Outlook

1 week from now

Dec 20, 2024  · BMO (TSX: BMO) Capital Markets anticipates that the approval and subsequent launch of suzetrigine for acute pain, expected in January 2025, will surpass current market …

investing.com

BMO Capital Markets Issues Pessimistic Forecast For Vertex ...

1 week from now

Dec 23, 2024  · Vertex Pharmaceuticals has a twelve month low of $377.85 and a twelve month high of $519.88. The stock has a market capitalization of $102.31 billion, a price-to-earnings …

etfdailynews.com

BMO Capital Markets Has Lowered Expectations For Vertex …

1 week from now

Dec 22, 2024  · Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target cut by investment analysts at BMO Capital Markets from $566.00 to $520.00 in a report …

defenseworld.net

Vertex Pharmaceuticals: Strategic Advancements And ... - Markets …

1 week from now

3 days ago  · Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of $520.00. Discover …

businessinsider.com

BMO Capital Cuts Price Target On Vertex Pharmaceuticals To $520 …

1 week from now

Dec 19, 2024  · -- Vertex Pharmaceuticals has an average rating of overweight and mean price target of $525.79, according to analysts polled by FactSet. Price: 391.19, Change: -56.31, …

marketscreener.com

Forecasting The Future: 13 Analyst Projections For Vertex ...

1 week from now

Jul 11, 2024  · BMO Capital: Raises: Outperform: $500.00: ... These ratings convey expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market. ...

nasdaq.com

Vertex (VRTX) PT Lowered To $520 At BMO Capital; 'Detour Not A …

1 week from now

Dec 20, 2024  · BMO Capital analyst Evan David Seigerman lowered the price target on Vertex (NASDAQ: VRTX) to $520.00 (from $566.00) while maintaining a Outperform rating.The …

streetinsider.com

Vertex Stock Rating Downgraded At Raymond James

1 week from now

Jan 3, 2025  · Goldman Sachs, BMO Capital Markets, and Stifel raised their price targets to $59, $52, and $52 respectively, reflecting optimism about Vertex's growth trajectory.

investing.com

BMO Cuts Vertex Target To $520, Stays Positive On Drug Outlook

1 week from now

Dec 20, 2024  · BMO Capital Markets anticipates that the approval and subsequent launch of suzetrigine for acute pain, expected in January 2025, will surpass current market expectations. …

investing.com

Truist Financial Has Lowered Expectations For Vertex …

1 week from now

Dec 25, 2024  · Vertex Pharmaceuticals has a 1 year low of $377.85 and a 1 year high of $519.88. The firm has a market capitalization of $105.12 billion, a PE ratio of -205.12 and a beta of 0.36.

etfdailynews.com

Vertex Shares Target Lifted To $52 On Growth Optimism

1 week from now

Nov 6, 2024  · The updated estimates and price target suggest that BMO Capital Markets sees Vertex as maintaining a steady performance, with potential upside from new growth vectors …

investing.com

14 Analysts Assess Vertex Pharmaceuticals: What You Need To Know

1 week from now

Jul 31, 2024  · BMO Capital: Raises: Outperform: $500.00: ... These ratings convey expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market. ...

nasdaq.com

What Analysts Are Saying About Vertex Pharmaceuticals Stock

1 week from now

Oct 1, 2024  · The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $500.53, a high estimate of $600.00, and a low estimate of $376.00.

nasdaq.com

BMO Capital Markets Has Lowered Expectations For Galiano Gold …

1 week from now

1 day ago  · Galiano Gold (TSE:GAU - Get Free Report) had its target price reduced by equities research analysts at BMO Capital Markets from C$3.50 to C$2.50 in a research note issued to …

marketbeat.com

Vertex Stock Sees Buy Rating Maintained With Potential Upsides …

1 week from now

Dec 23, 2024  · The stock has experienced significant pressure, falling over 15% in the past week. The firm's analyst lowered the target to $460 from the previous $550 while maintaining a Buy …

investing.com

Vertex Stock Sees Buy Rating Maintained With Potential Upsides …

1 week from now

Dec 23, 2024  · Despite this, BMO Capital Markets projects suzetrigine revenues to reach $145 million by 2025, surpassing the consensus estimate. Finally, JPMorgan's analysis anticipates …

investing.com

Vertex Shares Boosted By BMO On Strong Q4, 2024 Outlook

1 week from now

Mar 1, 2024  · On Friday, BMO Capital Markets adjusted its price target for Vertex (NASDAQ: VRTX) Inc. (NASDAQ: VERX), a tax compliance software provider, raising it to $35.00 from …

investing.com

Vertex Pharmaceuticals Reaches All-time High At $499 - Investing.com

1 week from now

Jul 25, 2024  · Analyst ratings varied, with RBC Capital maintaining a Sector Perform rating but adjusting its price target from $424 to $421, while BMO Capital Markets raised its price target …

investing.com